Hi @Outlander2, thank you for your post outlining the Saegen...

Hi @Outlander2, thank you for your post outlining the Saegen approach to cancer treatment and your great explanation comparing to our approach (IMU obviously).

For any one that read your post, I think that it’s also worth highlighting that the Seagen market cap in the US is currently US$37.5Billion!

This is roughly 70 times higher than the current IMU market cap.

To have our current treatments and status, even worthy of being included in the same conversation of where Seagen are, is remarkable and in my opinion, indicates how grossly undervalued we currently are.

I note that you also hold MSB and NEU, as do I.

Having held NEU for over 11 years, it is very gratifying to finally enjoy and share in part their remarkable success.

We can only hope that in the not too distant future, ourselves and our fellow IMU LTH’s, will enjoy similar success.

In my opinion the current share price is an unworthy and unfair reflection of what the team at IMU have achieved to date.